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The retinoblastoma tumor suppressor protein (RB) plays an
important role in biological processes such as cell cycle control,
DNA damage repair, epigenetic regulation, and genome stability. The canonical model of RB regulation is that cyclinCDKs phosphorylate and render RB inactive in late G1/S,
promoting entry into S phase. Recently, monophosphorylated
RB species were described to have distinct cell-cycleindependent functions, suggesting that a phosphorylation
code dictates diversity of RB function. However, a biologically
relevant, functional role of RB phosphorylation at non-CDK
sites has remained elusive. Here, we investigated S838/T841
dual phosphorylation, its upstream stimulus, and downstream
functional output. We found that mimicking T-cell receptor
activation in Jurkat leukemia cells induced sequential activation of downstream kinases including p38 MAPK and RB S838/
T841 phosphorylation. This signaling pathway disrupts RB and
condensin II interaction with chromatin. Using cells expressing
a WT or S838A/T841A mutant RB fragment, we present evidence that deﬁciency for this phosphorylation event prevents
condensin II release from chromatin.

The retinoblastoma tumor suppressor protein (RB) is well
characterized for its role in regulating entry into the cell cycle,
and this is its canonical function. In G1, RB is bound to E2F
transcription factors, repressing their ability to express cell
cycle target genes (1, 2). Upon growth stimulation, cyclin D
accumulates and binds to cyclin-dependent-kinases 4/6
(CDK4/6). Cyclin D-CDK4/6 complexes phosphorylate RB,
partially relieving E2F repression (3). This leads to expression
of cyclin E, and cyclin E-bound CDK2 hyperphosphorlyates
RB. Hyperphosphorylated RB is thought to be inactivated, and
free E2F transcription factors drive gene expression required
for subsequent cell cycle progression (4–6).
This model, however, represents only one facet of RB
function, and CDK-independent roles are emerging. These
noncanonical functions are ascribed to a pool of chromatinbound RB that localizes to various parts of the genome. For
example, RB is required for recruiting DNA repair machinery
for nonhomologous end joining (NHEJ) and homologydirected repair (HR) pathways at double-strand breaks
* For correspondence: Frederick A. Dick, fdick@uwo.ca.

(DSBs) (7, 8). In addition, RB recruits epigenetic writers to
repetitive elements that deposit repressive histone marks
(9, 10). Heterochromatinization of repetitive elements may be
required to silence their transcription to avoid an autoimmune
response and maintain chromosome stability (10–13). In
particular, RB-dependent maintenance of histone 4 lysine 20
tri-methylation (H4K20me3) at pericentromeric repeats is
required for proper chromatid segregation in anaphase (10).
Furthermore, disrupting RB interaction with structural maintenance of chromatin containing complexes such as condensin
II at pericentromeric repeats results in mitotic errors, replication defects, and aneuploidy (14, 15). Therefore, existing
literature suggests that there is a pool of RB that is resistant to
CDK inactivation and binds chromatin to carry out cell-cycleindependent functions.
Mechanistically, posttranslational modiﬁcations regulate
RB’s diverse functions (16). Notably, phosphorylation of RB
can regulate its cell-cycle-independent functions. For example,
CDK4/6 phosphorylation of RB at S249/T252 allows RB to
bind and inactivate the NFκB family protein p65 and its
immune-suppressive transcriptional program in prostate cancer cells (17). In addition, stress-induced p38 mitogenactivated protein kinase (MAPK) activation phosphorylates
RB at S249/T252 to negate inactivation by CDKs and prevent
cell cycle entry (18). Furthermore, monophosphorylation of RB
at its 13 CDK phosphorylation sites confers ability to activate
distinct transcriptional programs beyond cell cycle genes such
as inﬂammatory response and mitochondrial oxidative phosphorylation (19). However, these studies have primarily
focused on phosphorylation at CDK consensus sites, and RB
phosphorylation at non-CDK sites and their functional outcomes are not fully characterized. Upon apoptotic stimulation,
p38 MAPK, but not CDKs, phosphorylates RB at non-CDK
sites and activates E2F1 transcription in a reporter assay
(20). Speciﬁc non-CDK phosphorylation sites and their relevance to cellular function remain to be elucidated.
Here, we characterize RB phosphorylation on S838 and
T841 (S838/T841) as a mechanistic link between T-cell receptor (TCR) activation and chromatin decondensation in
Jurkat T-cells. Prompted by existing phospho-proteomic data,
we generated an antibody speciﬁc to phosphorylation at S838/
T841. We show that p38 MAPK is an upstream kinase that
induces RB phosphorylation at these sites upon stimulus that
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mimics TCR activation in culture. Finally, we demonstrate that
inability to phosphorylate these sites leads to defective condensin II release from chromatin.

Results
Detection of C-terminal RB phosphorylation on S838 and T841
Multiple residues located throughout RB are phosphorylated, and the functional roles of CDK sites have been extensively characterized. Many of these modiﬁcations serve to
inactivate its canonical function of negatively regulating cell
cycle entry through E2F transcription factor binding. Interestingly, RB monophosphorylation of CDK sites has been
shown to activate speciﬁc molecular functions of RB that may

extend beyond cell cycle control (19). We sought to identify
RB phosphorylation at new sites and determine their roles in
RB regulation.
Figure 1A depicts the open reading frame of RB, its known
CDK phosphorylation sites (top), and potential phosphoacceptor residues that are uncharacterized (bottom). We
focused on RB C-terminus (RBC) as it forms an α-helix, and
any phosphorylation within this region is likely to disrupt
protein–protein interactions, leading to a novel functional
outcome. To identify candidate phosphorylation sites for our
investigation, we curated predicted phosphorylation events
within tryptic fragments corresponding to RBC from available
phospho-proteomic data in different cells or tissues upon
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Figure 1. Putative phosphorylation of the RB C-terminus. A, the open reading frame for RB is shown depicting known CDK phosphorylation sites (top)
and uncharacterized, non-CDK phosphorylation sites in RBC (bottom). RB N-terminal domain (RBN), A and B halves of the pocket domain, and RB C-terminal
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various treatments (Fig. 1B) (21–29). A positive prediction for
each serine or threonine residue is shaded in blue.
The phospho-proteomic data reveal that various combinations of serine and threonine residues within RBC are readily
phosphorylated, supporting the idea that the RB phosphorylation “code” is yet incomplete. There is signiﬁcant variability
between the data sets on which exact sites are phosphorylated.
This may indicate that complex, differential phosphorylation
events occur in RBC depending on the cell type and stimulus,
or that whole cell proteomics cannot accurately discern between neighboring phosphorylation events. While all of these
potential modiﬁcations can be found in untreated cells, we
focused on S838 and T841 phosphorylation because it is
inducible upon TCR activation, a relevant signaling pathway in
Jurkat leukemic T-cells.
In order to study S838 and T841 phosphorylation on RB
further, we sought to generate a speciﬁc antibody for these
modiﬁcations. We generated rabbit antiserum against an RBderived peptide corresponding to amino acids 834 to 845,
phosphorylated on S838 and T841. An ELISA was performed
to conﬁrm the speciﬁcity of our antibodies following puriﬁcation from the antiserum. We found that anti-RB pS838/
pT841antibodies had a tenfold higher afﬁnity for the S838/
T841 phosphorylated RB peptide than its unphosphorylated
counterpart (Fig. 2A). Next, we sought to ﬁnd evidence for RB
phosphorylation on S838/T841 in vitro as predicted by
phospho-proteomic data. We incubated glutathione S-transferase-tagged RBC (GST-RBC) with whole cell extract (Ext)
from Jurkat cells treated with phosphatase inhibitors pervanadate and calyculin A (PVA/CA) to globally activate kinases
that may phosphorylate RB. We found a time-dependent increase in RB S838/T841 phosphorylation in the presence of
ATP (Fig. 2B). To account for the possibility that our antibody
cross-reacts with other phosphorylation events in RBC (amino
acids 792–928), we repeated the experiment with GST-RBC
where S838 and T841 were substituted to alanine either
together or as single mutants. This reveals that this antibody
requires either S838 or T841 phosphorylation, but not both
(Fig. 2C). For this reason, we describe the antibodies and
detected phosphorylation events throughout this paper as
pS838/pT841 because phosphorylation of either site alone, or
both in combination, is possible. With the speciﬁcity of our
antibody established, we determined if endogenous RB is
phosphorylated on S838/T841. We treated Jurkat cells with
PVA/CA to activate kinases and RB phosphorylation, prepared
nuclear extracts (NE), and immunoblotted with our antibody.
RB phosphorylation on S838/T841 was increased upon PVA/
CA treatment, but it was also evident that our antibody crossreacted with approximately six or seven proteins other than RB
(Fig. 2D). To ensure we were certain of RB’s identity, we
repeated the cell treatment and immunoprecipitated total RB
from Jurkat NE and performed an immunoblot with anti-RB
pS838/pT841antibodies. Once again, we conﬁrmed that RB
phosphorylation on S838/T841 was induced upon PVA/CA
treatment (Fig. 2E). In all subsequent experiments, we ﬁrst
immunoprecipitated RB, then probed with the antibody to
assess S838/T841 phosphorylation.

These data demonstrate that our antibody is highly speciﬁc
for phosphorylation within RBC, namely on S838/T841.
Although it cross-reacts with a small number of nuclear proteins, ﬁrst enriching for RB by immunoprecipitation is a robust
and speciﬁc means of detecting phosphorylation of these sites.
More importantly, we have shown the ﬁrst line of evidence
that S838/T841 phosphorylation is a bona ﬁde RB posttranslational modiﬁcation that has not yet been studied
functionally.
Sequential activation of kinases in the TCR signaling pathway
induces RB S838/T841 phosphorylation
As a ﬁrst step to understanding the functional role for RB
S838/T841 phosphorylation, we sought to identify the kinase
that was responsible for this modiﬁcation. p38 MAPK has been
shown to phosphorylate RB even when CDK sites are mutated
(20). Therefore, we pretreated Jurkat cells with a p38 inhibitor,
SB203580, then stimulated phosphorylation with PVA/CA.
We found that SB203580 pretreatment strongly reduced RB
S838/T841 phosphorylation despite PVA/CA treatment
(Fig. 3A). As a positive control for p38 inhibition, we also
measured phosphorylation of a known p38 target, MAPKAPK2, and found that phosphorylation of its activation loop at
T334 was also reduced. Next, we determined if immunoprecipitated p38 can phosphorylate RB at S838/T841 in vitro. We
ﬁrst isolated p38 by immunoprecipitating the active form with
anti-p38 pT180/pY182 phosphorylation-speciﬁc antibodies. It
was then incubated with GST-RBC in the presence or absence
of its inhibitor. p38 phosphorylation of RB increased over time,
and its inhibitor largely abrogated this effect (Fig. 3B).
These experiments strongly suggest that RB phosphorylation at S838/T841 is dependent on p38. PVA/CA treatment
indiscriminately activates kinases, yet selective inhibition of
p38 was sufﬁcient to reduce RB phosphorylation to background level. Furthermore, partially puriﬁed, active p38 was
necessary and sufﬁcient to induce RB phosphorylation in vitro
suggesting it may do so directly.
PVA/CA treatment has served as a way to easily and efﬁciently induce phosphorylation of RB. However, this treatment
activates many pathways and hence does not offer insight into
speciﬁc stimuli that induce RB S838/T841 phosphorylation
under physiological conditions. Since p38 is a downstream
target of T-cell receptor (TCR) signaling, and Jurkat cells are
leukemic T-cells, we hypothesized that TCR activation phosphorylates RB through p38. We mimicked TCR activation
by treating cells with an antibody cocktail that physically
aggregates TCR and its costimulatory receptor together,
as previously reported (30, 31). We then detected
phosphorylation-dependent activation of proteins in the
signaling pathway by immunoblotting. We observed rapid
activation of ZAP70 within the ﬁrst 5 min of antibody crosslinking and peak activation of p38 soon after at 15 min
(Fig. 4A). TCR activation reproducibly induced p38 activation
within the ﬁrst 30 min (Fig. 4B). At 30 min we immunoprecipitated RB and found strong S838/T841 phosphorylation
(Fig. 4C). In addition, TCR activation did not induce additional
J. Biol. Chem. (2021) 296 100108
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Figure 2. Detection of phosphorylation of S838/T841 on RB. A, rabbit antiserum was generated by immunizing animals with a peptide phosphorylated
at S838 and T841. Phosphorylation-speciﬁc antibodies were puriﬁed and an ELISA was performed to determine their speciﬁcity. Phosphorylated or
unphosphorylated peptides were adhered to microplate wells and incubated with anti-RB pS838/pT841antibodies. Control wells contained either no
peptide or no antibody. Antibody binding was measured colorimetrically and graphed. B, a GST-tagged RBC fragment (aa 792–928) was incubated with
PVA/CA-treated Jurkat whole cell extract for the indicated times, and omission of ATP was used as a negative control. Phosphorylation status was
determined by immunoblotting with the anti-RB pS838/pT841, and blotting with anti-RB antibodies was used as a loading control. C, WT or mutant GST-RBC
proteins were incubated with PVA/CA-treated Jurkat extracts with or without ATP for 20 min. Phosphorylation status was measured as in B. D, S838/T841
phosphorylation of endogenous RB was detected by western blotting with anti-RB pS838/pT841 antibodies in PVA/CA-treated Jurkat nuclear extracts (NE).
This membrane was stripped and reprobed for RB, and the arrow indicates the corresponding RB band. E, jurkat cells were treated with PVA/CA, and RB was
immunoprecipitated from NE with an α-RB antibody-coupled to Protein G Dynabeads. Phosphorylation status of S838/T841 was determined by western
blotting.

phosphorylation of neighboring CDK phosphorylation sites,
S807 and S811 consistent with these cells already being in a
proliferative state. S838/T841 phosphorylated RB also retained
its interaction with E2F1 and E2F2 as they were comparably
coimmunoprecipitated relative to untreated cells. The shift in
E2F2 migration upon TCR activation is consistent with previous proteomic data that report S117/S123 phosphorylation
in Jurkat cells upon PVA/CA or TCR activation (25, 29).
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These experiments implicate TCR activation as a relevant
mechanism that induces RB S838/T841 phosphorylation and
suggests that RB S838/T841 phosphorylation may regulate its
noncanonical functions. Our antibody cocktail treatment appears to closely mimic TCR activation as both ZAP70 and p38
were activated sequentially in the anticipated order. A slight
temporal delay in peak phosphorylation of ZAP70, p38, and
ultimately RB also suggests that this signaling cascade is
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Figure 3. Phosphorylation of RB on S838/T841 is dependent on p38. A,
jurkat cells were treated with PVA/CA with or without 10 μM SB203580, a
p38 inhibitor. RB was immunoprecipitated from lysates with an α-RB antibody bound to Protein G Dynabeads, and phosphorylation of S838/T841
was detected by immunoblotting. As a positive control for p38 inhibition,
phosphorylation of a known p38 phosphorylation target, T334 on
MAPKAPK-2, was detected by western blotting. B, jurkat cells were treated
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Immunoprecipitated p38 was resuspended in kinase buffer containing GSTRBC, with or without 50 μM SB203580 for the indicated amount of time.
Phosphorylation of S838/T841 and GST-RBC was detected by western
blotting as indicated.

biologically relevant to TCR activation. Furthermore, because
S838/T841 phosphorylation in response to TCR signaling is
unlinked to CDK phosphorylation, its function is unlikely to be
related to cell cycle entry or control of E2F-dependent
transcription.
RB S838/T841 phospho-acceptor mutants prevent condensin II
unloading and chromatin decondensation
The majority of previously described RB function stems
from its ability to occupy chromatin. For example, RB protects
genome integrity during mitosis by recruiting the condensin II
complex to pericentromeric heterochromatin (15). In addition,
the condensin II complex has a role in developing T-cells. The
nessy mutant allele of CAPH2, one of the subunits of the
complex, results in defective condensation of T-cell chromatin
and development (32, 33). Since RB is phosphorylated under
conditions that mimic TCR signaling, and is known to recruit

condensin II to chromatin, we hypothesized that RB S838/
T841 phosphorylation may regulate RB–condensin II interactions on chromatin in T-cells.
In order to compare chromatin occupancy upon TCR
cross-linking, we ﬁrst sought to establish that this stimulus
did not affect total expression of the proteins of interest.
Indeed, we conﬁrmed that expression of CAPH2, RB, E2F1,
and SMC1, a cohesin subunit, was not changed in whole cell
extracts (Fig. 5A, left). However, TCR cross-linking for
30 min induced release of RB, E2F1, and CAPH2, but not
SMC1 from chromatin (Fig. 5A, right). Using densitometric
analysis of these experiments, we found that TCR crosslinking released 40% of CAPH2 from chromatin (Fig. 5B).
To examine the precise role of S838/T841 phosphorylation in
this process, we created a phospho-acceptor mutation in RB
with a S838A/T841A double alanine substitution. To stably
express this mutant in cells, we generated lentiviral vectors
coding for HA-tagged large pocket fragment of RB (RBLP,
amino acids 379–928). Jurkat cells were transduced with
lentiviruses expressing either the WT RBLP (RBLP-WT) or
S838A/T841A (RBLP-AA) construct (Fig. 5C). We conﬁrmed
equivalent expression of both constructs by immunoblotting
for the HA-tag (Fig. 5D). We cross-linked TCRs as before and
investigated CAPH2 and SMC1 chromatin levels (Fig. 5E).
This revealed that RBLP-AA expressing cells retained similar
levels of chromatin-bound CAPH2 as unstimulated cells and
that RBLP-WT expressing cells released CAPH2 similarly to
untransduced Jurkat cells (Fig. 5E). We normalized CAPH2
release to SMC1-bound chromatin levels to quantitate the
inhibition of CAPH2 release by RBLP-AA (Fig. 5F). These
experiments conﬁrm that the inability to phosphorylate RB at
S838/T841 dominantly blocks condensin II release from
chromatin.
Next, we sought to describe a biochemical consequence of
defective CAPH2 unloading. To assess changes in chromatin
structure upon TCR cross-linking, we used sensitivity to
sonication-induced chromatin shearing as a readout for
chromatin compaction as previously reported (Fig. 6A) (33).
Untreated or TCR cross-linked cells were ﬁxed to immobilize
DNA–protein contacts and fractionated to obtain total chromatin. Isolated chromatin was sheared by a range of sonication
cycles, and the presence of high-molecular-weight DNA fragments was detected by agarose gel electrophoresis and
ethidium bromide staining. In line with Figure 5A, TCR crosslinking decreased the amount of high-molecular-weight DNA
remaining after the same number of sonication cycles
compared with control cells that were untreated (Fig. 6, B–C).
We repeated this TCR cross-linking experiment using cells
that express RBLP-WT or the -AA mutant. This revealed that
chromatin isolated from RBLP-AA expressing cells was
sheared less effectively compared with that from RBLP-WT
expressing cells (Fig. 6, D–E). This suggests that the RB
S838A/T841A mutant disrupts TCR cross-link-mediated
chromatin decondensation and suggests that the phosphorylation of RB on these sites plays a key role in chromatin
decondensation by releasing RB and condensin II from
chromatin.
J. Biol. Chem. (2021) 296 100108
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Discussion
In this report, we characterized a functional role for nonCDK phosphorylation of RB. By curating existing phosphoproteomic data, we generated and validated S838/T841
phospho-speciﬁc antibodies. With this tool, we showed that
p38 MAPK is an upstream kinase that can direct RB phosphorylation and that TCR cross-linking induces a signaling
cascade that ultimately phosphorylates RB in Jurkat cells on

these sites. To probe its mechanistic role, we generated cell
lines that stably express phospho-acceptor mutant RB. Finally,
our data demonstrates that when RB is unable to be phosphorylated at S838/T841, TCR signaling is unable to release
condensin II from chromatin. This conclusion is consistent
with previous work that describes RB–condensin II chromatin
interactions and T-cell development and contributes to our
understanding of an emerging RB phosphorylation code.
J. Biol. Chem. (2021) 296 100108
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Figure 6. RB S838/T841 phosphorylation regulates chromatin dynamics upon T-cell receptor signaling. A jurkat cells were stimulated by T-cell receptor cross-linking as indicated. Cells were ﬁxed and lysed to obtain chromatin fractions. Chromatin was sonicated for one to three cycles. Protein–DNA
cross-links were reversed, and DNA was puriﬁed and analyzed on a 3% agarose gel. DNA was stained with ethidium bromide and visualized on a Chemi Doc.
The high-molecular-weight DNA band indicated by the arrow was quantiﬁed on Image Lab, and intensity is expressed as a percentage of the total lane
normalized within each group. B, untransduced Jurkat cells were PBS or TCR cross-linked as described in A. Chromatin fragmentation is shown. C, percent
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TCR cross-linking induced marked loss of chromatin-bound
CAP-H2, but not SMC1, suggesting large-scale, yet selective
reorganization of chromatin architecture. Importantly,
expression of RBLP-AA was sufﬁcient to disrupt TCR crosslinking-induced CAP-H2 release. The selective nature of RB
regulation of condensin II in Jurkat T-cells agrees with the
previous characterization of the nessy mutant CAP-H2 allele
that is responsible for defective T-cell differentiation. Recently
published work may inform future studies on speciﬁc consequences of the release of CAP-H2 in this model. CAP-H2 and
transcription factor IIIC (TFIIIC) localize to histone clusters in
mouse embryonic stem cells and serve to maintain topologically associated domains that regulate transcription (34). In
addition, RB-condensin II complexes can regulate transcription at bidirectional promoters and maintain long-range
chromosomal interactions. ChIP-sequencing (ChIP-Seq) for
condensin II and TFIIIC components upon TCR cross-linking
may inform site-speciﬁc loss of interaction, and the mechanistic role of RB can be delineated with a phospho-acceptor RB
mutant. For increased sensitivity, gene editing technologies
should be adopted to mutate endogenous RB or deplete
endogenous RB with an inducible system as previously reported. ChIP-seq data should be interpreted together with
high-throughput chromosome conformation capture (3C)
such as 4C-seq to fully characterize functional consequences.
We speculate that RB phosphorylation at S838/T841 may be
a key step in naive T-cell activation. Previous work has
demonstrated that chromatin condensation orchestrated by
condensin II is required to avoid cell death in developing
thymocytes (33). Once mature, these cells become quiescent.
Upon TCR activation through cognate antigen binding and
costimulation, re-entry into cell cycle is coupled with chromatin decondensation and nuclear expansion in naïve T-cells.
Loss of CAP-H2 chromatin occupancy upon TCR crosslinking in Jurkat T-cells is in line with such macromolecular
changes during T-cell activation. Furthermore, TCR crosslinking with CD3/CD28 antibodies speciﬁcally induced RB
phosphorylation at S838/T841, but not at its CDK sites. RB
interaction with E2F transcription factors was also unaffected.
These data suggest that S838/T841 phosphorylation is functionally distinct from canonical cell cycle control by RB that
may also be cell type speciﬁc. Future work with peripheral Tcells ex vivo is warranted to support this model.
Ultimately, our work adds a layer of complexity to
phosphorylation-dependent regulation of RB function. The
canonical model of cell cycle control by RB has been binary;
cyclin-CDK-driven RB hyperphosphorylation renders RB’s
negative regulation of E2F transcription factors inactive.
Recently, however, various monophosphorylated RB species at
one of its CDK sites have been shown to regulate cell-cycleindependent transcription programs. We showed that cellcycle-independent TCR cross-linking induces a signaling

cascade via p38 that can ultimately phosphorylate RB at S838/
T841. Future work is warranted to characterize the relevance
and functional roles of S838/T841 phosphorylation in other
physiological circumstances.

Experimental procedures
Antibodies
Anti-RB pS838/pT841 antibody was produced in rabbits by
Covance (Pennsylvania, USA). The peptide immunogen corresponded to the sequence 834-SIGE(pS)FG(pT)SEKF-845 of
pRB. Peptides were immobilized using the Sulfo-link coupling
reagent (Thermo Fisher) following the manufacturer’s recommendations. The phospho-speciﬁc antibody was puriﬁed
using standard procedures by passing serum ﬁrst over the
nonphosphorylated peptide column and secondly over the
phosphorylated-peptide column to remove any antibodies
recognizing the nonphosphorylated species. Anti-RB pS838/
pT841 antibody was used in primary antibody solution at
0.5 mg/ml for Western blotting. Anti-MAPKAPK-2 pT334
(27B7), p38 pT180/pY182 (9211), total p38 (9212), α-tubulin
(11H10), and RB pS807/pS811 (9308) antibodies were obtained from Cell Signaling Technology. Anti-HA antibody
(3F10) was from Sigma. Anti-pRB monoclonal antibody (G3245) was from BD Pharmingen, pRB rabbit polyclonal antibodies and E2F1 antibody (C-20) were from Santa Cruz, CAPH2 antibody (A302-275A) was from Bethyl Laboratories. Antirabbit or anti-mouse IgG goat antibody conjugated to HRP
was from GE Healthcare. For TCR activation studies, antiCD3ε (OKT3) and CD28 (CD28.2) antibodies were from
BioLegend, and light chain-speciﬁc goat anti-mouse IgG (115005-174) was from Jackson ImmunoResearch Labs.
Cell culture and stimulation
Suspension Jurkat cells were grown in DMEM enriched with
10% v/v FBS, L-glutamine, penicillin, and streptomycin at 37

C in 5% CO2. For SB203580 inhibitor pretreatment, Jurkat
cells (107) were suspended in 5 ml enriched DMEM and
SB203580 (Cell Signaling Technology) was added from 10 mM
stock to a ﬁnal concentration of 10 μM. Equal volume of
DMSO was added to control samples. The cells were then
incubated at 37  C for 2 h until treatment with pervanadate
and calyculin (PVA/CA). Cells were centrifuged at 300g for
5 min at 4  C and washed twice with PBS. After the last wash,
the pellet was resuspended in 5 ml enriched DMEM, and PVA/
CA was added to a ﬁnal concentration of 100 and 0.1 μM,
respectively. Control samples received equal volumes of PBS
and DMSO vehicles, respectively. Both groups were incubated
at 37  C for 20 min. TCR activation was achieved as previously
described with modiﬁcations (21). Jurkat cells (5 × 106) were
resuspended in 1 ml enriched media and treated with 5 μg/ml
anti-CD3ε and CD28 antibodies and 30 μg/ml goat anti-mouse

high-molecular-weight DNA quantities were averaged and graphed (n = 3, * indicates p < 0.05, two-way ANOVA with Sidak’s multiple comparisons test). D,
lentiviral transduced Jurkat cells were stimulated by T-cell receptor cross-linking, ﬁxed, and lysed to obtain chromatin fractions. Chromatin was sonicated for
increasing number of cycles and analyzed as in A. E, the high-molecular-weight band indicated by the arrow was quantiﬁed, averaged, and graphed, (n = 3,
* indicates p < 0.05, Two-way ANOVA with Sidak’s multiple comparisons test).
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IgG to cross-link the primary antibodies. The cells were then
incubated for indicated times at 37  C, after which they were
harvested.
Protein extract preparation
All of the following lysis buffers were supplemented with
250 μM Na3VO4, 5 mM NaF, 1 mM PMSF, 5 μg/L aprotinin,
and leupeptin immediately before use. For whole cell extract
(Ext), cells were washed twice with cold PBS and resuspended
in lysis buffer containing 25 mM Tris-Cl pH 7.5, 100 mM
NaCl, 5% (v/v) glycerol, and 1% (v/v) NP-40 and incubated on
ice for 10 min. Insoluble material was cleared by centrifugation
at 12,000g at 4  C for 10 min. For NE, cells were washed twice
with cold PBS, resuspended in hypotonic lysis buffer containing 10 mM Tris-Cl pH 7.5, 10 mM KCl, 3 mM MgCl2,
1 mM EDTA, and 0.05% (v/v) NP-40, and incubated on ice for
5 min. Nuclei were isolated by centrifuging the suspension at
1300g at 4  C for 5 min. The pelleted nuclei were washed twice
in the same buffer. The nuclei were lysed in buffer containing
20 mM Tris-Cl pH 7.5, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 25% (v/v) glycerol, 0.1% (v/v) NP-40 and incubated on
ice for 10 min. Insoluble material was cleared by centrifugation
at 12,000g at 4  C for 10 min. For chromatin fractionation, PBS
washed cells were incubated for 10 min on ice in buffer containing 10 mM Tris-Cl pH 8.0, 10 mM KCl, 1.5 mM MgCl2,
0.34 M sucrose, 10% (v/v) glycerol, and 0.1% (v/v) Triton X100 to lyse outer membrane. Nuclei were isolated by centrifuging the suspension at 1300g at 4  C for 5 min. The pelleted
nuclei were washed twice in the same buffer without Triton X100. The nuclei were lysed in buffer containing 3 mM EDTA
and 0.2 mM EGTA for 30 min on ice with occasional mixing.
Nucleoplasmic fraction was removed by centrifuging the lysate
at 4000g at 4  C for 5 min. Remaining chromatin fraction was
solubilized with DNaseI treatment at 37  C for 10 min in
buffer containing 10 mM Tris-Cl, 2.5 mM MgCl2, 0.5 mM
CaCl2. Protein concentration was quantiﬁed by Bradford assay
following standard procedures.
Immunoprecipitation
Antibodies to RB or pp38 T180/Y182 were diluted 1:50 in
Ext containing 1 to 2 mg total protein. The lysates were
incubated at 4  C overnight with gentle agitation. In total, 50 μl
Dynabeads Protein G (Thermo Fisher) was added and incubated at 4  C for 2 h with gentle agitation. A magnet was used
to immobilize the beads and to discard the supernatant.

E. coli BL21 (DE3) and puriﬁed with Glutathione Sepharose 4B
(Sigma) following the manufacturer's recommendation. The
reactions were prepared on ice, then transferred to 37  C to
start the assay. After the given incubation times, the immunoprecipitated proteins were immobilized with a magnet, and
the remaining supernatant was saved.
SDS-PAGE, immunoblotting, and Coomassie staining
Protein extracts, supernatants, and immunoprecipitated
beads were diluted in SDS-PAGE sample buffer to a ﬁnal
concentration of 62.5 mM Tris-Cl pH 6.8, 10% glycerol, 2%
SDS, 72.5 mM β-mercaptoethanol, and 0.005% bromophenol
blue. SDS-PAGE was performed following standard procedures. After gel electrophoresis, proteins were transferred to
PVDF membrane and incubated with primary antibodies
diluted in 5% milk or BSA in TBS-T over night at 4  C with
gentle agitation. Membranes were washed ﬁve times in tris
buffered saline-Tween 20 (TBS-T) for 5 min and incubated
with horseradish peroxidase (HRP)-conjugated goat secondary
antibody for 1 h at room temperature. Membranes were
washed again, incubated in SuperSignal WestDura (Thermo
Fisher) for 5 min protected from light, and developed on a
ChemiDoc (Bio-rad). For Coomassie staining, gels were
washed three times in water and incubated in GelCode Blue
(Thermo Fisher) over night at room temperature with gentle
agitation. Stained gels were washed again twice in water. Bands
were imaged on a ChemiDoc.
Plasmids and lentiviral transduction
Brieﬂy, pSicoR-Ef1a-mCh-Puro (Addgene #31845) was
double-digested with AfeI and SmaI to replace mCherry coding sequence with that of RBLP with matching sticky ends inframe. S838A/T841A substituted plasmid was made with
QuikChange Site-directed mutagenesis kit (Agilent), following
manufacturer’s recommendations and mutagenic primers
TTAGTATCAATTGGTGAAGCATTCGGGGCTTCTGAGAAGTTCCAGAAA and TTTCTGGAACTTCTCAGAAGCCCCGAATGCTTCACCAATTGATACTAA. HEK293 T cells
at 70% conﬂuency on 10-cm plates were transfected with 12 μg
expression vector, 9 μg pMD2.G (Addgene #12259), and 3 μg
psPAX2 (Addgene #12260) using Lipofectamine 3000 (Life
Technologies) following manufacturer’s recommendations. Two
days later, the cell media was harvested and passed through
a 0.45 μm ﬁlter. Jurkat cells (106) were transduced with the
ﬁltrate containing 8 μg/ml polybrene. Transduced Jurkat cells
were maintained in 0.3 μg/ml puromycin.

In vitro kinase assay
Immunoprecipitated pp38 T180/Y182-Dynabeads complexes were used in kinase assays similar to previous reports.
The complexes were resuspended in 50 μl kinase buffer containing 25 mM Tris-Cl pH 7.5, 5 mM β-glycerophosphate,
10 mM MgCl2, 0.25 mM Na3VO4, and 5 mM NaF. Each of the
time points consisted of a 40 μl reaction containing 5 μl of
immunoprecipitated kinase or WCE (where indicated), 10 μg
of GST-RBC, 1 mM ATP, and 50 μM SB203580 (where indicated) in kinase buffer. GST fusion proteins were expressed in
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Chromatin sonication
Jurkat cells were washed twice in PBS and ﬁxed in 1%
formaldehyde/PBS for 10 min at room temperature with gentle
agitation. Fixation was quenched with 0.125 M glycine for
5 min at room temperature. Cells were washed twice in cold
PBS and incubated for 10 min on ice in buffer containing
10 mM HEPES pH 6.5, 10 mM EDTA, 0.5 mM EGTA, and
0.25% Triton X-100. Nuclei were isolated by centrifuging the
suspension at 600g at 4  C for 5 min. The pelleted nuclei were
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lysed and washed twice in buffer containing 10 mM HEPES pH
6.5, 10 mM EDTA, 0.5 mM EGTA, and 200 mM NaCl.
Chromatin isolated from 3 million cells was resuspended in
300 μl of buffer containing 50 mM Tris-Cl pH 8.0, 1 mM
EDTA, 0.5% Triton X-100, and 1% SDS and aliquoted into
1.5 ml microtubes (Diagenode). All of the above lysis buffers
were supplemented with 250 μM Na3VO4, 5 mM NaF, 1 mM
PMSF, 5 μg/L aprotinin, and leupeptin immediately before use.
Chromatin was sonicated in Bioruptor Pico (Diagenode) at 4

C with one to three cycles. Each cycle consisted of 15 s ON
and 30 s OFF. After sonication, chromatin–protein complexes
were reverse-cross-linked by adding NaCl to a ﬁnal concentration of 200 mM to each sample and incubating overnight at
65  C. RNA and protein were removed by RNase A and proteinase K digestion, respectively. DNA was isolated by phenolchloroform extraction and ethanol precipitation and analyzed
on 3% agarose gels. DNA was stained with ethidium bromide
and visualized on a Chemi Doc. High-molecular-weight DNA
bands were quantiﬁed as a percentage of the total lane intensity with lower threshold cutoff at 100 bp using Image Lab
5.2.
Statistical analysis
All statistical analyses were performed on Prism 8. CAPH2
chromatin loading relative to SMC1 in untransduced cells was
compared using Student’s t-test. That of HA-RBLP WT or AA
expressing cells was compared using two-way ANOVA and
Sidak’s multiple comparisons test. For sonicated chromatin
densitometry, the mean of triplicate values was compared
between treatment conditions, or cell lines, as indicated by
two-way ANOVA. Sidak’s multiple comparison test was used.

Data availability
All data are contained within the manuscript.
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